Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 18;7(2):330-4.
doi: 10.3980/j.issn.2222-3959.2014.02.25. eCollection 2014.

A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG

Curt Hartleben-Matkin  1 , Diddier Prada  2 , Rafael Mancilla-Vences  1
Affiliations

A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG

Curt Hartleben-Matkin et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the long-term response to the fixed combination of dorzolamide/timolol in patients with primary open angle glaucoma (POAG) and the addition of other intraocular pressure (IOP) lowering medications such as prostaglandin analogs and brimonidine.

Methods: A retrospective, non-randomized, and descriptive clinical study was performed with 182 eyes diagnosed with POAG. Patients were divided into three groups: a group with fixed combination of dorzolamide/timolol only, a second group with prostaglandin analogs plus fixed combination of dorzolamide/timolol, and a third group with the addition of brimonidine to the same fixed combination. IOP data were gathered retrospectively and the differences between groups were calculated.

Results: IOP was reduced satisfactorily in all three groups; however, a progressive IOP reduction was noted in the group with the fixed combination plus prostaglandin analogs. In this group, a progressive, significant and more homogeneous response of the reduction was noted in comparison with the other groups.

Conclusion: IOP reduction was efficacious in all three groups. The addition of prostaglandin analogs showed progressive IOP reduction, progressive response and absence of long-term drift. Brimonidine did not show a significant additive effect.

Keywords: Cosopt®; brimonidine; dorzolamide/timolol; fixed combination; glaucoma; prostaglandin analogs.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Boxplot of baseline IOP in all groups of analysis
A significant statistical difference between groups was find (P=0.023). Cosopt®: 2% dorzolamide/0.5% timolol; Cosopt®+PG: Cosopt®+prostaglandin analogs; Cosopt®+B: Cosopt®+brimonidine. *Outlier data.
Figure 2
Figure 2. Mean IOP at baseline and follow-up in patients with POAG (adjusted)
*: Statistically significant difference between groups.
Figure 3
Figure 3. Percentage of IOP reduction on each group
A: Cosopt®; B: Cosopt®+P; C: Cosopt®+B. Cosopt®: 2% dorzolamide/0.5% timolol; Cosopt®+PG: Cosopt®+prostaglandin analogs; Cosopt®+B: Cosopt ®+brimonidine.
Figure 4
Figure 4. IOP in Cosopt®+PG group at 4y of analysis
Statistical significant differences between periods of treatment are shown. Cosopt®+PG: Cosopt®+prostaglandin analogs. *Outlier data.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cedrone C, Mancino R, Cerulli A, Cesareo M, Nucci C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res. 2008;173:3–14. - PubMed
    1. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefansson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359–393. - PubMed
    1. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–720; discussion 829–730. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. - PubMed
    1. Yeh J, Kravitz D, Francis B. Rational use of the fixed combination of dorzolamide-timolol in the management of raised intraocular pressure and glaucoma. Clin Ophthalmol. 2008;2(2):389–399. - PMC - PubMed

LinkOut - more resources